Latest Regulatory News

Nexus Minerals has acquired Northern Star’s remaining 10% stake in the Pinnacles Gold Project, boosting its ownership to 100% and ending the joint venture. The deal includes a 1.5% net smelter return royalty payable to Northern Star, with an option to buy back part of it.

ResMed is offloading its MatrixCare business in a $490 million cash deal, reinforcing its strategic pivot towards high-growth sleep and connected care markets. The sale proceeds will fuel shareholder returns and innovation investments.

Catalina Resources is gearing up for a ~2,200m reverse circulation drilling campaign at its Kirkalocka Gold Project in WA’s Mid-West, following promising historical data and recent fieldwork across four priority gold targets.

Sibelco Silica Pty Ltd has exercised its call option to inject an additional $4.4 million into the Diatreme joint venture, restoring ownership stakes and supporting key project milestones for the Northern Silica Project in Far North Queensland.

Taiko Critical Minerals has secured $7 million through a wholesale placement and launched a $3 million Share Purchase Plan to fund key development stages of its Barrytown Minerals Project, including feasibility studies and regulatory approvals.

Frasers Group has escalated its takeover tussle for Accent Group by applying to the Takeovers Panel, disputing Accent’s claims that the offer undervalues the company and seeking orders for additional disclosure or an independent expert review.

Marquee Resources (ASX:MQR) is raising just over $1 million through a non-renounceable rights issue priced at half a cent per share, accompanied by free attaching options. The capital raise aims to support ongoing exploration and the recent acquisition of the Tungsten Mountain Project in Nevada.

Santana Minerals has reported strong high-grade gold intercepts from initial infill drilling at its Rise and Shine deposit, bolstering confidence in the early-stage open pit mine plan and supporting upcoming financing efforts.

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.

Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.

The Supreme Court of New South Wales has approved the scheme of arrangement for Rubik Australia to acquire Qube Holdings, setting the stage for trading suspension and ownership transfer.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.